DDInter1676 DDInter1602
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.
Risankizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Risankizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Risankizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Risankizumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Risankizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Risankizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Risankizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Risankizumab may lead to a major life threatening interaction when taken with Upadacitinib